...We Welcome You To The Resverlogix HUB On AGORACOM!

** Apabetalone (RVX-208) Currently Being Tested in a Phase 3 BETonMACE Cardiovascular Outcomes Trial ** Trial is Fully Enrolled and Top-Line Results Expected Q1 2019

Free
Message: Abstract - first example of a "curative" effect?

Interesting for sure

The resistance to BETi’s appears to be linked to increased NfKb which when inhibited restores sensitivity to BETi’s

check out latest PubMed abstract on Brd4, which wasnt JQ1

 

Share
New Message
Please login to post a reply